Dateline City:
KENILWORTH, N.J.
Results of First Phase 3 Trial Anticipated in Late 2017
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the publication of research conducted by Merck
scientists on the discovery and development of verubecestat, an
investigational small molecule inhibitor of the enzyme beta-site amyloid
precursor protein cleaving enzyme 1 (BACE1), for the potential treatment
of Alzheimers disease (AD).
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orIan McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more